Published in N Engl J Med on September 22, 1977
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg (1999) 3.56
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg (1978) 2.94
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16
A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg (1982) 2.09
A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg (1981) 2.09
Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg (1991) 2.06
Recent advances in the care of the patient with malignant melanoma. Ann Surg (1997) 1.92
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol (2016) 1.45
Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg (1994) 1.41
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg (1983) 1.26
Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg (1988) 1.19
Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol (2009) 1.18
Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data. Int J Clin Oncol (2009) 1.15
Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10
Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg (1996) 1.09
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-1, an international multicenter trial. Ann Surg (2007) 1.06
Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg (1985) 1.02
Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol (2010) 1.00
Malignant melanoma. Practical considerations concerning prophylactic regional lymph node dissection. Ann Surg (1987) 0.96
Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg (1984) 0.93
Surgical management of melanoma: an EORTC Melanoma Group survey. Ecancermedicalscience (2013) 0.93
Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or systemic injection. Ann Surg (1986) 0.91
Assessment of biopsy techniques and histopathologic interpretations of primary cutaneous malignant melanoma. Ann Surg (1979) 0.91
Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg (2002) 0.87
The treatment of state I melanoma of the extremities with regional hyperthermic isolation perfusion. Ann Surg (1982) 0.86
Combined endoscopic and open inguinal dissection for malignant melanoma. Langenbecks Arch Surg (2003) 0.85
Surgical aspects of subungual malignant melanomas. The Scottish Melanoma Group. Ann Surg (1992) 0.84
Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. Nat Rev Clin Oncol (2010) 0.84
Judging prognosis in malignant melanoma of the skin. A problem of inference over small data sets. Ann Surg (1983) 0.83
Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis (2008) 0.83
A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann Surg (1984) 0.83
Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation. Oncotarget (2015) 0.83
Malignant melanoma of the head and neck: a brief review of pathophysiology, current staging, and management. Ochsner J (2008) 0.80
Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland. Ann Surg Oncol (2006) 0.78
Cutaneous melanoma of the breast. Ann Surg (1979) 0.77
Current status of sentinel lymph node biopsy in solid malignancies. World J Surg Oncol (2004) 0.77
Malignant melanoma (non-metastatic). BMJ Clin Evid (2007) 0.75
Cure and cosmesis in the management of primary malignant melanoma. Br J Cancer (1990) 0.75
Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. JAAD Case Rep (2015) 0.75
Sentinel node biopsy in breast cancer. Effect on patients must be considered. BMJ (1999) 0.75
Management of regional lymph node basins in melanoma. Ochsner J (2010) 0.75
Cutaneous lesions of the nose. Head Face Med (2010) 0.75
Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.75
Diagnosis, treatment and prognosis of early melanoma. The importance of depth of microinvasion. Ann Surg (1980) 0.75
The Veronesi quadrantectomy: an historical overview. Ecancermedicalscience (2017) 0.75
Sentinel node biopsy versus elective lymph node dissection in patients with cutaneous melanoma in a Japanese population. Int J Clin Oncol (2007) 0.75
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68
Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53
Breast cancer (1) N Engl J Med (1992) 4.79
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J (1970) 2.91
Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J (1971) 2.82
Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care (1996) 2.80
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (1991) 2.58
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg (1991) 2.55
Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46
Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer (1981) 2.40
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer (1977) 2.33
Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15
Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci (1986) 2.07
The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06
Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol (1986) 2.05
Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer (1992) 2.01
Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol (2002) 1.98
TIA-1 and TIAR activate splicing of alternative exons with weak 5' splice sites followed by a U-rich stretch on their own pre-mRNAs. J Biol Chem (2001) 1.96
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
UV-damaged DNA-binding protein in the TFTC complex links DNA damage recognition to nucleosome acetylation. EMBO J (2001) 1.81
Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer (1978) 1.75
Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer (1976) 1.75
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68
Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer (1983) 1.65
Postoperative radiotherapy in breast cancer--long-term results from the Oslo study. Int J Radiat Oncol Biol Phys (1986) 1.62
Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62
Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst (1997) 1.60
Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol (1999) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Morbidity and mortality after hepatic resection of metastases from colorectal cancer. Br J Surg (1995) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med (1998) 1.53
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat (1985) 1.51
Hypercalcaemia in B cell chronic lymphocytic leukaemia. Br J Haematol (1994) 1.50
Osteoblastic meningioma of the lateral ventricle. Case illustration. J Neurosurg (1999) 1.50
Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg (1983) 1.50
Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49
Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J (2001) 1.48
Florence statement on breast cancer, 1998 forging the way ahead for more research on and better care in breast cancer. Eur J Cancer (1999) 1.48
Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer (1987) 1.48
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47
Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med (1996) 1.46
Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial. Minerva Anestesiol (2015) 1.46
Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg (1987) 1.46
Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer (2001) 1.44
Drop-outs in tamoxifen prevention trials. Lancet (1999) 1.44
Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer (1996) 1.43
Proceedings: The value of staging laparotomy in non-Hodgkin's lymphomas (with emphasis on the histiocytic type). Cancer (1974) 1.43
Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol (2009) 1.43
TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology (1999) 1.42
Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine. J Pediatr Hematol Oncol (1996) 1.42
Surgical approach to internal mammary lymph node biopsy. J Am Coll Surg (2001) 1.42